The University of Washington has joined the Alliance for Therapies in Neuroscience (ATN), a long-term research partnership between academia and industry geared to transform the fight against brain diseases and disorders of the central nervous system.
Launched in 2021 by UCSF, UC Berkeley, Genentech — a member of the Roche group — and Roche Holding AG, the ATN seeks to accelerate the development of new therapies for a broad range of brain and central nervous system conditions, such as Alzheimer’s disease, Lou Gehrig’s disease, Huntington’s disease, Parkinson’s disease, autism, depression and psychiatric disorders. As part of the ATN, Genentech and Roche committed up to $53 million over 10 years for research at the ATN’s participating academic institutions, a collaboration that is unique for both its duration and the breadth of its ambitions.
As part of the ATN, scientists across the UW — including the College of Engineering, the College of Arts & Sciences and the School of Medicine — will “be integrated with academic and industry partners in a way that has simply never been done before,” according to Dr. Tom Daniel, the Emeritus Joan and Richard Komen Endowed Chair in the UW Department of Biology and incoming CEO of the Washington Research Foundation, who led efforts to join the ATN.
Read the full story on UW News.